TY - JOUR
T1 - Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals
AU - Hofmann, Jonathan N.
AU - Birmann, Brenda M.
AU - Teras, Lauren R.
AU - Pfeiffer, Ruth M.
AU - Wang, Ye
AU - Albanes, Demetrius
AU - Baris, Dalsu
AU - Colditz, Graham A.
AU - De Roos, Anneclaire J.
AU - Giles, Graham G.
AU - Hosgood, H. Dean
AU - Lan, Qing
AU - Landgren, Ola
AU - Liao, Linda M.
AU - Rothman, Nathaniel
AU - Weinstein, Stephanie J.
AU - Pollak, Michael N.
AU - Neuhouser, Marian L.
AU - Purdue, Mark P.
N1 - Funding Information:
This work was supported by the Intramural Research Program of the NIH, National Cancer Institute; by NIH grants K07 CA115687, RO1 CA 127435, R01 CA149445, UM1 CA186107, P01 CA87969, R01 CA49449, and UM1 CA167552; and by the American Cancer Society grant RSG-11-020-01-CNE (B.M. Birmann). M.N. Pollak's laboratory is funded in part by a grant from the Terry Fox Foundation, Vancouver, Canada. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S.Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The NCI funded the PLCO Cancer Screening Trial, which was also supported by contracts from the Division of Cancer Prevention of the NCI and by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher Copyright:
© 2016 AACR.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.
AB - The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.
UR - http://www.scopus.com/inward/record.url?scp=84963768563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963768563&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-15-2406
DO - 10.1158/0008-5472.CAN-15-2406
M3 - Article
C2 - 26921332
AN - SCOPUS:84963768563
VL - 76
SP - 1935
EP - 1941
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 7
ER -
